Abstract
Background: Catheter related bloodstream infections (CRBSIs) are a common complication in hemodialysis (HD) patients with central venous catheters (CVCs), often caused by Methicillin Resistant Staphylococcus aureus (MRSA). Vancomycin is the preferred first line treatment for MRSA related CRBSI. At Hospital Pakar Sultanah Fatimah (HPSF), the current protocol for CRBSI in HD patients involves a weight-based intravenous (IV) vancomycin loading dose (LD) of 25 mg/kg, followed by therapeutic drug monitoring (TDM) within 48 hours post administration. This study evaluates the adequacy of the initial dosing regimen in achieving the target serum vancomycin concentration (SVC) of 15 to 20 mcg/ml. Methods: A retrospective cross-sectional study was conducted among hospitalized HD patients receiving IV vancomycin from July 1, 2022, to July 31, 2023. Data were collected from TDM request orders in the Pharmacy Information System (PhIS). The primary outcomes analyzed were the proportion of patients achieving the target SVC and factors influencing vancomycin pharmacokinetics. Multiple linear regression was used to assess associations between SVC and variables such as time to first sampling (TTFS), age, and initial vancomycin dose. Results: A total of 106 TDM samples were analyzed. The mean vancomycin LD was 1568.2 mg (SD 303.6), with a mean TTFS of 41.2 hours (SD 11.8). Only 32.1% of patients achieved the target SVC, while 56.6% had subtherapeutic levels and 11.3% had supratherapeutic levels. Multiple linear regression identified TTFS (p=0.003), age (p=0.002), and initial dose (p=0.004) as significant predictors of SVC. Conclusion: The current vancomycin dosing protocol at HPSF does not consistently achieve therapeutic SVC in HD patients with CRBSI. Increasing the LD to 25 to 35 mg/kg and optimizing TTFS within 24 to 48 hours may improve target attainment. Further studies are needed to validate these findings and refine vancomycin dosing strategies in HD patients. Keywords: Vancomycin, catheter-related bloodstream infections, hemodialysis, therapeutic drug monitoring, dosing adequacy, Methicillin-Resistant Staphylococcus aureus (MRSA).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Medical Research Ethics Committee Malaysia gave ethical approval for this work with reference number 24-02412-PBR
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos